HWGB Biotech engages principal lawyer of Foster Garvey PC to explore business opportunities in US healthcare industry
KUALA LUMPUR, June 30, 2020 - HWGB Biotech Sdn Bhd is pleased
to announce that the company has engaged Jeffrey Qiong Li, the principal lawyer
of Foster Garvey PC to help exploring business opportunities in the US
HWGB Biotech Sdn Bhd, formerly known as HWG Consortium
Sdn Bhd, is a wholly-owned subsidiary of main-board listed company Ho Wah
Genting Berhad (HWGB, 9601). The group has recently proposed diversification of
its existing businesses to include the healthcare-related industry such as the
dietary supplement, biotechnology and healthcare technology sub-segments.
Foster Garvey is one of the largest legal firms based
in the Pacific Northwest. With attorneys located in six cities across the
United States and in Beijing, Foster Garvey Business attorneys help companies
navigate an increasingly complex operating environment and work with them to
understand their business goals and priorities in order to find the right
solutions for their organizations.
By leveraging Mr. Jeffrey Qiong Li’s extensive
business network in both US and China, HWGB Biotech Sdn Bhd hopes that it is
able to tap or venture into the healthcare industry worldwide, especially to
the US market.
Foster Garvey’s extensive experience allow them to
capably serve the needs of companies in highly regulated industries such as
transportation, banking and financial services, health care and
HWGB BioTech aims to
provide a comprehensive range of big health products and solutions that adopts
a preventive measure readily available to improve the livelihood of Malaysians.
Foster Garvey PC
was established through the combination of Foster Pepper PLLC and Garvey
Schubert Barer, PC, in 2019. Foster Garvey is one of the largest firms based in
the Pacific Northwest with six offices in Seattle, Portland, Washington, D.C.,
New York, Spokane and Beijing. The firm provides clients, including several of
the most influential and innovative companies, governments and individuals in
the country, with an extended national and international reach across the full
spectrum of legal services.
Jeffrey has extensive
experience assisting companies in their capital-raising activities, including
public offerings of equity and debt securities, private placements and
registered direct offerings.
Jeffrey is the Co-Chair
of the firm’s China Practice, and represents China companies on their outbound
investments and mergers and acquisitions in the United States. He has advised
Chinese strategic buyers (operating companies) and private equity funds in their
acquisitions of chemical, pharmaceutical and machinery companies in the United
States. Jeffrey has advised Chinese companies on corporate laws, including
formation of new companies and establishment of joint ventures in the United
States. In addition, he has advised U.S. companies on Chinese corporate and
foreign investment laws, such as stock acquisition of Chinese companies, and
has assisted in patent litigation and licensing in China.